CM With MO CM Without MO
Fremanezumab Fremanezumab
Quarterly(n = 201) Monthly(n = 198) Placebo(n = 188) Quarterly(n = 174) Monthly(n = 177) Placebo(n = 188)
HIT-6
 LSM (SE) −6.0 (0.7) −6.9 (0.6) −4.5 (0.7) −7.0 (0.7) − 6.8 (0.64) −4.5 (0.6)
  LSMD (SE) − 1.5 (0.7) −2.4 (0.7) −2.4 (0.7) − 2.3 (0.7)
  P value 0.0356 0.0009 0.0006 0.0012
MSQoL, RFR
 LSM (SE) 19.6 (1.8) 21.4 (1.8) 14.7 (1.9) 21.9 (2.0) 21.6 (2.0) 14.5 (1.9)
  LSMD (SE) 4.9 (2.0) 6.7 (2.0) 7.4 (2.1) 7.1 (2.1)
  P value 0.0142 0.0008 0.0005 0.0008
MSQoL, RFP
 LSM (SE) 17.5 (1.7) 18.4 (1.6) 14.2 (1.7) 16.4 (1.7) 14.2 (1.7) 10.2 (1.7)
  LSMD (SE) 3.2 (1.8) 4.2 (1.8) 6.2 (1.8) 3.9 (1.8)
  P value 0.0696 0.0200 0.0007 0.0290
MSQoL, EF
 LSM (SE) 20.2 (2.0) 22.0 (1.9) 17.3 (2.0) 22.4 (2.1) 19.7 (2.1) 16.7 (2.1)
  LSMD (SE) 2.9 (2.2) 4.7 (2.2) 5.7 (2.3) 3.0 (2.3)
  P value 0.1833 0.0305 0.0118 0.1873
PHQ-9
 LSM (SE) −2.8 (0.4) −2.3 (0.4) −2.4 (0.4) −2.6 (0.4) −2.3 (0.4) −1.6 (0.4)
  LSMD (SE) −0.5 (0.4) 0.0 (0.4) −1.0 (0.4) −0.7 (0.4)
  P value 0.2679 0.9678 0.0155 0.0922